261 related articles for article (PubMed ID: 34672766)
1. REDD1 deletion attenuates cancer cachexia in mice.
Hain BA; Xu H; VanCleave AM; Gordon BS; Kimball SR; Waning DL
J Appl Physiol (1985); 2021 Dec; 131(6):1718-1730. PubMed ID: 34672766
[TBL] [Abstract][Full Text] [Related]
2. Loss of REDD1 prevents chemotherapy-induced muscle atrophy and weakness in mice.
Hain BA; Xu H; Waning DL
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1597-1612. PubMed ID: 34664403
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin K activity controls cachexia-induced muscle atrophy via the modulation of IRS1 ubiquitination.
Meng X; Huang Z; Inoue A; Wang H; Wan Y; Yue X; Xu S; Jin X; Shi GP; Kuzuya M; Cheng XW
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1197-1209. PubMed ID: 35098692
[TBL] [Abstract][Full Text] [Related]
5. Obesity worsens mitochondrial quality control and does not protect against skeletal muscle wasting in murine cancer cachexia.
Cardaci TD; VanderVeen BN; Bullard BM; McDonald SJ; Unger CA; Enos RT; Fan D; Velázquez KT; Frizzell N; Spangenburg EE; Murphy EA
J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):124-137. PubMed ID: 38062911
[TBL] [Abstract][Full Text] [Related]
6. REDD1 deletion prevents dexamethasone-induced skeletal muscle atrophy.
Britto FA; Begue G; Rossano B; Docquier A; Vernus B; Sar C; Ferry A; Bonnieu A; Ollendorff V; Favier FB
Am J Physiol Endocrinol Metab; 2014 Dec; 307(11):E983-93. PubMed ID: 25315696
[TBL] [Abstract][Full Text] [Related]
7. Disruption of REDD1 gene ameliorates sepsis-induced decrease in mTORC1 signaling but has divergent effects on proteolytic signaling in skeletal muscle.
Steiner JL; Crowell KT; Kimball SR; Lang CH
Am J Physiol Endocrinol Metab; 2015 Dec; 309(12):E981-94. PubMed ID: 26487002
[TBL] [Abstract][Full Text] [Related]
8. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
9. Activation of Akt-mTORC1 signalling reverts cancer-dependent muscle wasting.
Geremia A; Sartori R; Baraldo M; Nogara L; Balmaceda V; Dumitras GA; Ciciliot S; Scalabrin M; Nolte H; Blaauw B
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):648-661. PubMed ID: 34741441
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.
Puppa MJ; Gao S; Narsale AA; Carson JA
FASEB J; 2014 Feb; 28(2):998-1009. PubMed ID: 24145720
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
12. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia.
AlSudais H; Rajgara R; Saleh A; Wiper-Bergeron N
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):743-757. PubMed ID: 35014202
[TBL] [Abstract][Full Text] [Related]
13. Ameliorating cancer cachexia by inhibiting cancer cell release of Hsp70 and Hsp90 with omeprazole.
Liu Z; Xiong J; Gao S; Zhu MX; Sun K; Li M; Zhang G; Li YP
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):636-647. PubMed ID: 34729960
[TBL] [Abstract][Full Text] [Related]
14. The time-course of cancer cachexia onset reveals biphasic transcriptional disruptions in female skeletal muscle distinct from males.
Morena da Silva F; Lim S; Cabrera AR; Schrems ER; Jones RG; Rosa-Caldwell ME; Washington TA; Murach KA; Greene NP
BMC Genomics; 2023 Jul; 24(1):374. PubMed ID: 37403010
[TBL] [Abstract][Full Text] [Related]
15. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
16. The Toll-Like Receptor/MyD88/XBP1 Signaling Axis Mediates Skeletal Muscle Wasting during Cancer Cachexia.
Bohnert KR; Goli P; Roy A; Sharma AK; Xiong G; Gallot YS; Kumar A
Mol Cell Biol; 2019 Aug; 39(15):. PubMed ID: 31138662
[TBL] [Abstract][Full Text] [Related]
17. A novel orthotopic mouse model replicates human lung cancer cachexia.
van de Worp WRPH; Theys J; González AS; van der Heyden B; Verhaegen F; Hauser D; Caiment F; Smeets HJM; Schols AMWJ; van Helvoort A; Langen RCJ
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1410-1423. PubMed ID: 37025071
[TBL] [Abstract][Full Text] [Related]
18. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
